RAN Binding Protein 17 (RANBP17) Antibody from ABBEXA LTD

Search, find, compare suppliers for anti-RAN Binding Protein 17 (RANBP17) antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityRAN Binding Protein 17 (RANBP17)
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman, mouse
Isotypen/a
Formatpeptide affinity purified
Size80 µl, 400 µl,
Concentrationn/a
ApplicationsELISA, WB
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThe transport of protein and large RNAs through the nuclear pore complexes (NPC) is an energy-dependent and regulated process. The import of proteins with a nuclear localization signal (NLS) is accomplished by recognition of one or more clusters of basic amino acids by the importin-alpha/beta complex; see MIM 600685 and MIM 602738. The small GTPase RAN (MIM 601179) plays a key role in NLS-dependent protein import. RAN-binding protein-17 is a member of the importin-beta superfamily of nuclear transport receptors.
ImmunogenKLH-conjugated synthetic peptide between 149-175 amino acids from the N-terminal region of human RANBP17.
Other NamesRan-binding protein 17, RANBP17, Ran-binding protein 17, Ran-binding protein 17, Ran-binding protein 17 , Ran-binding protein 17 , RANBP17, RANBP17, RANBP17 , RANBP17
Gene, Accession #RANBP17, UniProt: Q9H2T7
Catalog #abx030354
Priceplease inquire
Order / More InfoRAN Binding Protein 17 (RANBP17) Antibody from ABBEXA LTD
Product Specific Referencesn/a
ABBEXA LTD
ABBEXA LTD
ABBEXA LTD
181 Cambridge Science Park
Cambridge, CB4 0GJ UK
P: +44 (0) 1223 755950

Customer Service: info@abbexa.com
Technical Support: support@abbexa.com
Orders: orders@abbexa.com

https://www.abbexa.com

U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413

Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950


Profile of ABBEXA LTD
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.